BACKGROUND-Medication non-adherence is common in Parkinson's disease (PD) and is associated with increased disability and healthcare costs. Individuals' beliefs regarding their medical conditions and treatments impact medication adherence. While instruments exist to measure patients' beliefs about medications in general, no such tool exists for PD.
Introduction
Despite the efficacy of pharmacotherapy in Parkinson's disease (PD), adherence to antiparkinsonian drugs is as low as 33% by electronic medication monitoring technology, which is much lower than self-report. [1, 2] Suboptimal adherence with PD medications is associated with worsening disability, higher hospitalization rates, and greater healthcare expenditures. [2, 3] The health belief model (HBM) provides a framework for exploring characteristics influencing health behaviors such as adherence. The HBM proposes that health behavior results from the interaction of three factors: 1) the existence of a salient health concern; 2) the perceived threat of that concern to one's wellbeing; and 3) the belief that a particular behavior would reduce the threat at an acceptable cost. Here, cost encompasses both financial burden and the effort required to overcome perceived barriers. [4] Critical to an individual's perceived cost-benefit analysis of treatment are the beliefs one holds about the therapy itself. Medication beliefs may be grouped into two categories: 1) benefits of a treatment versus 2) the risks of said treatment or concerns held by the individual. [5] Instruments evaluating medication beliefs have been validated in multiple conditions, however, prior studies of patient-held beliefs in PD have described unique medication and symptom-specific phobias that are absent from such instruments. For example, patients often endorse fears surrounding the use of levodopa and the risk of developing dyskinesias. [6] [7] [8] [9] Such fears may significantly influence adherence [7, 9, 13] . [6, 9, 10] Adherence is also associated with demographic and clinical characteristics such as age, education, low health literacy, neuropsychiatric symptoms, disease severity, quality of life, polypharmacy, and medication cost in non-PD cohorts. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Emerging evidence suggests that these characteristics shape patients' beliefs about their health and treatments, and such beliefs form a potentially actionable obstacle to adherence. [5, [21] [22] [23] [24] [25] Figure 1 illustrates our conceptual model to explain the characteristics shaping adherence in PD, with beliefs as an intermediary. Our objectives were to develop an instrument and conduct an initial pilot study to capture patient beliefs about PD medications, explore the associations of demographic and clinical characteristics with these beliefs, and define the relationship between beliefs and adherence. We hypothesized that older age, low health literacy, depression, apathy, and poor quality of life would be associated with negative medication beliefs in PD. We further postulated that positive beliefs would predict higher adherence.
Materials and Methods
Item generation, scale development, revision, and psychometric testing were accomplished in the following phases: initial focus groups for item generation and scale development, expert review of items, a second round of focus groups for content validity, and psychometric testing in a separate validation cohort. The study was approved by the University of Pennsylvania Institutional Review Board.
Subjects
Focus groups-We conducted 6 focus groups that consisted of a purposive sample of patients with PD or caregivers of patients drawn from existing local PD support groups Validation cohort-Subjects in the validation cohort were drawn from an existing longitudinal cohort study, the University of Pennsylvania Udall Center for Parkinson's Research. These subjects had a diagnosis of PD based on established criteria, were 50 years of age or older, and had a score of ≥20 on the Montreal Cognitive Assessment (MoCA) at the time of the validation study visit. [26, 27] Subjects in the validation cohort did not participate in the focus groups.
Item generation and scale development
We employed the nominal group technique (NGT) for item generation. [28] After a warm-up exercise, participants went through cycles of NGT for 3 separate stimulus questions. The questions were: how PD had affected participants' lives, the key benefits of the dopaminergic medications taken for PD-either perceived or experienced; and the key risks of dopaminergic medications. Three initial focus groups were held, after which individual responses to the benefit and risk prompts were categorized into thematic groupings. The most common themes were converted to 24 items and scored on a 5-point Likert scale, ranging from "strongly disagree" (1 point) to "strongly agree" (5 points). applicability, and missing themes. The modified draft was then presented to a second round of focus groups for revision based on similar criteria. Based on these responses, the instrument wording was revised to include lay explanations of symptoms, and named the PD Medication Beliefs (PD-Rx) instrument.
Psychometric testing
The PD-Rx was administered to a cross-sectional sample of non-demented subjects with PD drawn from the Udall Center. We enrolled subjects who presented for an initial enrollment or annual follow-up visit between May 2013 and May 2014.
Primary Variables of Interest-In addition to data collected as part of the Udall study (described in detail elsewhere [29, 30] and briefly below), the PD-Rx was administered along with the Brief Medication Questionnaire (BMQ). The BMQ is a validated instrument to measure adherence. [31] The BMQ asks for each medication taken in the past week, including the name, strength, frequency of daily doses, number of doses missed, and indication. Subsequent questions ask whether the subject experiences specific problems with his medications (side effects, trouble remembering all doses, trouble affording medications, etc.). To assess test-retest reliability of the PD-Rx, a second copy of the instrument was mailed to all subjects within two weeks of their study visit.
We assessed adherence in two ways. First, the BMQ Adherence Risk Score (ARS) as mentioned above. [31] The ARS is scored categorically 0-4, with points given for 1) nonadherence with current drug regimen, 2) negative beliefs or motivational barriers, 3) recall barriers, and 4) access barriers. Second, we reviewed the subject's electronic medical record to obtain the medication list documented by the subject's neurologist from the most recent clinical visit or telephone encounter immediately preceding the study visit. All dopaminergic medications were converted to levodopa-equivalent doses (LEDs). [32] Chart review was conducted while blinded to BMQ and PD-Rx responses. Each physician-listed medication was compared to the subject-listed medications in the BMQ. The difference between the subject and physician total LED yielded a percentage LED adherence, with <80% or >120% defined as non-adherent.
Covariates of Interest-Demographic and clinical characteristics included age at PD diagnosis and duration of symptoms. The Unified Parkinson's Disease Rating Scale (UPDRS) was used to capture disease severity. [33, 34] The Hoehn and Yahr scale was used to classify the stage of PD. [35] Apathy was scored from 0-4 based on one UPDRS item, where 4 indicates complete loss of initiative. [34] The 15-item Geriatric Depression Scale was used to measure depressive symptoms, with scores ≥6 indicating depressed mood. [36] Quality of life was assessed using the Parkinson's Disease Questionnaire (PDQ-39) scored from 0-100 where higher scores denote poorer quality of life. [37] Health literacy was assessed with the Newest Vital Sign (NVS), a brief screening instrument that requires no handwriting and is untimed. [38] 
Statistical analysis
Item response frequencies were reviewed for non-response, "not applicable" answers, and floor and ceiling effects for item reduction. [39] Cronbach's alpha was calculated to estimate internal consistency of the scale. Exploratory factor analysis was used to examine construct validity and identify unique domains. [40] Test-retest reliability was assessed using an intraclass correlation coefficient. Univariate analyses were conducted between the PD-Rx total score and individual covariates, using chi-square, t-tests, or ANOVA, as appropriate. Multivariable linear regression analyses were conducted using backwards stepwise elimination with PD-Rx total score as the dependent variable, and any covariates with pvalue <0.2 in univariate analyses. Model fit was assessed by likelihood ratio testing.
The association between PD-Rx and ARS was modeled using ordered logistic regression.
The proportional odds assumption was tested via likelihood ratio testing. The association between PD-Rx score and binary LED adherence was examined using logistic regression. All statistical analyses were two-sided with significance set at <0.05 level. Data analysis was performed using STATA 12.1 (StataCorp, College Station, TX).
Results

Sample Characteristics
Six focus groups ranged in size from 7 to 16 members for a total of 38 participants; 71% were patients and 29% caregivers. A total of 75 subjects participated in the validation cohort; their characteristics are displayed in Table 1 . Significant apathy or depressed mood at the time of the study visit was uncommon, however 28% of the sample endorsed antidepressant use. By ARS criteria, 81.3% of subjects had at least two out of four barriers to adherence.
Item Generation and Scale Development
Initial items fell into several themes: 1) positive themes, including improvements in motor and non-motor symptoms, and restoration of normalcy; 2) negative themes such as known adverse effects, disruption of daily activity due to regimen complexity, and financial burden; and 3) future concern themes of tachyphylaxis, "running out of options", and neuroprotection.
Expert reviewers recommended the removal of 7 original items, yielding 17 items in the pilot PD-Rx, none of which had >5% missing data. Item-level distribution of scores ranged from 1-5 for all except for one item. After factor analysis 3 items not specific to PD were deleted, as were 3 items with ≥20% "not applicable" responses. Table 2 shows the final 11item PD-Rx scale and the percent choosing each option. The total possible score ranges from 11-55, with higher scores indicating benefits outweighing risks, or more positive medication beliefs.
self-efficacy, current adverse effects, and future concerns. As the 3 factors explained only 58.3% of score variance, factor-based scoring was rejected in favor of an overall score. Testretest reliability based on a subset of 56 subjects was 0.47 for the total score, and ranged from 0.00 to 0.60 for the individual items, as shown in Table 3 . Table 4 shows unadjusted associations of medication beliefs with the covariates of interest. Depressed mood and poorer quality of life were inversely correlated with PD-Rx scores (p = 0.02 and p <0.01, respectively). There was no association between PD-Rx score and the number of PD medications or total number of medications taken (p = 0.76, and 0.85, respectively). Table 5 displays the associations of individual covariates after adjusting for demographics and disease stage. Depressed mood was not independently associated with medication beliefs (p = 0.56), however the relationship between poor quality of life and negative beliefs remained significant (−0.13 points on PD-Rx for every point on PDQ-39, p = 0.04).
Associations of PD-Rx Scores with Covariates of Interest
Associations of PD-Rx Scores with Adherence Measures
Using the ARS, with higher scores indicative of non-adherence, every point on the PD-Rx was associated with a 0.87-fold lower odds of non-adherence (95% CI 0.79-0.95, p <0.01). This indicates that benefit-predominant beliefs are associated with fewer barriers to adherence. The association between PD-Rx and binary adherence, defined as 80-120% LED concordance, trended to significance, with an odds ratio of 1.11 for every point on the PD-Rx (95% CI 0.99-1.25, p = 0.07).
Discussion
We identified medication beliefs held by diverse populations of patients with PD and their caregivers and coalesced 11 common beliefs about dopaminergic medications covering both necessities and concerns into a patient-centered instrument with reasonably good psychometric characteristics. Poorer quality of life was associated with a lower total score on the PD-Rx (more negative beliefs), and lower scores were also related to at least one measure of adherence.
Two surprising findings in our study were the low overall test-retest reliability of the PD-Rx total score (0.47) and the highly variable reliability of individual items. Certain items were particularly susceptible to change; in particular, prompts such as "Taking my PD medications improves how fast or easily I move" or "Taking my PD medications makes walking easier"-had very low intra-class correlation coefficients. We hypothesize that subjects responded based on their functional status at the moment of instrument completion. As bradykinesia, rigidity, and certain components of gait are sensitive to on-and offmedication states that may fluctuate throughout the course of a day, responses to such questions may indicate a direct medication effect. Other items appear to probe more stable, non-state-dependent beliefs, such as offering some control over PD or slowing its progression. Therefore, an individual's subjective weighting of necessities versus concerns may vary over the course of a single day in parallel with PD motor fluctuations. The alternative explanation is that the items are not adequately capturing the domains we believe them to be. Further revisions of the PD-Rx will include an item indicating "on" or "off" medication state, and we will examine the test-retest reliability between fluctuators and nonfluctuators to determine whether medication states affect the reporting of beliefs.
Both depressed mood and poorer quality of life were associated with lower PD-Rx scores, and poorer quality of life remained independently associated with negative beliefs after adjusting for confounders. This supports the hypothesis that medication beliefs may be a mediator between clinical characteristics and adherence. By identifying a patient with depressed mood or poor quality of life as potentially non-adherent, the clinician takes the first step towards intervening on behavior. However, without understanding the specific beliefs motivating that individual's behavior, one-size-fits-all interventions will remain the suboptimal standard.
Other covariates associated with non-adherence in prior work-such as education, racial minority, age, and low health literacy-were not significantly correlated with beliefs in the current study. For the former three, we may have failed to detect an association due to having a highly educated, nearly entirely white sample without much variability in age. Health literacy was also not related to beliefs. Prior studies finding that successful adherence required adequate health literacy relied upon pharmacy refill records as their measure of adherence, and our choice of adherence measures may have biased our results towards the null. [17] Although we hypothesized that apathy and depressed mood might bias the estimation of risk in PD treatment, neither characteristic was independently associated with beliefs. This may be due to the lower than expected prevalence of both apathy and depressed mood in our sample. [41] However, 28% of our sample was treated with an antidepressant, suggesting that pharmacologic treatment blunted our ability to detect a signal. [42] Because of the exploratory nature of this study, we relied on self-report and physiciandocumented medication lists to calculate PD medication adherence. Similar to prior PD studies relying on self-report, we found 25% of our sample was non-adherent by LED criteria. [2, 43] This is likely an underestimate. Studies using pharmacy refill data and pill counts have detected non-adherence approaching 67% and higher. [43] Therefore our results are likely biased towards the null.
This exploratory study has several limitations. First, there are potential sampling and healthy volunteer biases. One attempt to overcome this limitation was to implement in-home study visits for subjects with limited mobility. However, this initial pilot was conducted with a small and demographically homogeneous sample and may be underpowered despite recruiting at least five subjects per item. Second, focus groups bear the risk of social desirability bias. We addressed this by drawing our focus group participants from preexisting support groups. [44] As mentioned above, patient-reported medication lists may significantly underestimate the prevalence of non-adherence, and provider-reported medication lists drawn from the electronic medical record are prone to errors. [45, 46] Future studies employing gold-standard adherence measures, such as electronic medication monitoring devices, will be critical for validation of the PD-Rx. Finally, whether further validation proves an association between beliefs and adherence, the possibility that such beliefs may be refractory to intervention must be considered.
In summary, we present the initial pilot of an instrument to assess the medication beliefs held by patients with PD. With the PD-Rx, we sought to identify the beliefs that underlie medication phobia and non-adherence. Similar to providers directly asking patients about adherence, we felt that directly asking patients about fear of medication would lead to biased responses. [47] Further research is indicated to determine the effect of on-and off-medication states on beliefs, to test the PD-Rx in different samples, to confirm the association between beliefs and adherence using more robust measures, and to develop targeted interventions. Non-adherent PD patients face significantly higher rates of acute care visits and annual medical costs, even after adjusting for comorbidities. [43] Understanding the patient and disease-specific factors influencing adherence could guide clinicians to individualize counseling and patient education, though this remains to be tested in PD. [48] 
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